➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Express Scripts

Last Updated: September 30, 2020

DrugPatentWatch Database Preview

Patent: 8,461,178

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

Summary for Patent: 8,461,178
Title:Naphthyridine derivatives and the use thereof as kinase inhibitors
Abstract: The present invention relates to kinase modulators of the naphthyridine type and to the preparation and use thereof as medicaments for the modulation of misdirected cellular signal transduction processes, in particular for influencing the function of tyrosine and serine/threonine kinases and for the treatment of malignant or benign tumors and other disorders based on pathological cell proliferation, such as, for example, restenosis, psoriasis, arteriosclerosis and cirrhosis of the liver.
Inventor(s): Schuster; Tilmann (Grossostheim, DE), Gerlach; Matthias (Brachttal, DE), Seipelt; Irene (Offenbach, DE), Polymeropoulos; Emmanuel (Frankfurt am Main, DE), Mueller; Gilbert (Frankfurt am Main, DE), Guenther; Eckhard (Maintal, DE), Marchand; Pascal (Nort-sur-Erdre, FR), Defaux; Julien (Dijon, FR)
Assignee: Aeterna Zentaris GmbH (Frankfurt, DE)
Application Number:12/953,680
Patent Claims:see list of patent claims

Details for Patent 8,461,178

Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Estimated Patent Expiration Status Orphan Source
Merck ELSPAR asparaginase VIAL 101063 001 1978-01-10   Start Trial Aeterna Zentaris GmbH (Frankfurt, DE) 2029-11-26 RX search
Genentech HERCEPTIN trastuzumab VIAL; INTRAVENOUS 103792 001 1998-09-25   Start Trial Aeterna Zentaris GmbH (Frankfurt, DE) 2029-11-26 RX Orphan search
Imclone ERBITUX cetuximab VIAL; INTRAVENOUS 125084 001 2004-06-18   Start Trial Aeterna Zentaris GmbH (Frankfurt, DE) 2029-11-26 RX Orphan search
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Number >Approval Date >Patent No. >Assignee >Estimated Patent Expiration >Status >Orphan >Source

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
Harvard Business School

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.